Receive updates from Bariatric News for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from Bariatric News. Unsubscribe at any time.
Site title: Latest | Bariatric News
Is this your feed? Claim it!
A case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention (LI) compared to LI alone, has found a significantly higher weight reduction, fat mass loss, and visceral fat loss in patients treated with the Allurion Smart Capsule combined with lifestyle intervention. At 36 weeks, Allurion Smart Capsule patients had an average weight reducti...
Viking Therapeutics has completed patient enrolment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obes...
A research team has developed a fluorescent probe that allows scientists to visualise how individual lipid droplets break down inside living cells in real-time. The probe changes its fluorescence properties depending on the chemical composition of each droplet, which allows researchers to observe not only their location within cells, but also their metabolic activity during lipi...
Obesity severity is incrementally associated with a broad range of cardiometabolic and renal disease burden, as discovered by researchers at Pennington Biomedical Research Center. In a presentation by Dr Florina Corpodean titled, ‘Associations of Obesity Severity with Cardiometabolic and Renal Disease Burden in the United States," at ObesityWeek 2025, she explored the relationsh...
Outcomes from the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) has met the primary endpoints and all key secondary endpoints. Innovent Biologics plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evalua...
